JPL Wealth Management LLC Purchases New Holdings in Novo Nordisk A/S (NYSE:NVO)

JPL Wealth Management LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 3,475 shares of the company’s stock, valued at approximately $299,000.

Other institutional investors also recently added to or reduced their stakes in the company. Apollon Wealth Management LLC boosted its stake in shares of Novo Nordisk A/S by 2.4% during the 3rd quarter. Apollon Wealth Management LLC now owns 38,835 shares of the company’s stock worth $4,624,000 after acquiring an additional 906 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd boosted its stake in shares of Novo Nordisk A/S by 57.8% during the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 10,275 shares of the company’s stock worth $1,243,000 after acquiring an additional 3,762 shares in the last quarter. Verus Capital Partners LLC boosted its stake in shares of Novo Nordisk A/S by 27.6% during the 3rd quarter. Verus Capital Partners LLC now owns 6,509 shares of the company’s stock worth $775,000 after acquiring an additional 1,408 shares in the last quarter. Ashton Thomas Private Wealth LLC boosted its stake in shares of Novo Nordisk A/S by 7.9% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 15,910 shares of the company’s stock worth $1,894,000 after acquiring an additional 1,165 shares in the last quarter. Finally, Savvy Advisors Inc. boosted its stake in shares of Novo Nordisk A/S by 69.1% during the 3rd quarter. Savvy Advisors Inc. now owns 3,728 shares of the company’s stock worth $444,000 after acquiring an additional 1,524 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 4.3 %

Shares of NVO opened at $74.75 on Thursday. The company has a market capitalization of $335.42 billion, a PE ratio of 22.72, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock has a fifty day moving average of $84.39 and a two-hundred day moving average of $103.83. Novo Nordisk A/S has a fifty-two week low of $73.80 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.